The Most Effective Hormone Replacement Therapies
Dr. Calise is a recognized expert in cognitive decline, neurological disorders, and Psycho Pharmacology and he has lectured extensively on these subjects. He is a compassionate physician who treats all of his patients as individuals. He is dedicated to a holistic approach to medicine resulting in the best possible patient care.
College of Staten Island
Staten Island, New York
B.S. 1974
Autonomous university of Guadalajara
Guadalajara, Mexico
M.D. 1979
New York Medical College
St. Joseph’s Hospital
Staten Island, New York
St. Vincent’s Medical Center
Staten Island, New York
1982 – 1983
Downtown Medical Center
Brooklyn, New York
1983-1986
Chief Resident
July 1985 – July1986
625 South East 3rd Avenue, # 400
Ft. Lauderdale, FL 33316
1986 – 1994
Calise,Steingo,Kishner, M.D., PA
Director : Memory Institute
5757 N. Dixie Highway
Ft. Lauderdale, FL 33334
1994 – 1999
Neurology Private Practice
572 – McNab St.
Pompano Beach , Fl 33339
2000 – 2009
2021 E Commercial Blvd.
Fort Lauderdale, Fl. 33308
2009 – 2018
#ME 48776
1986
#145708
1986
Diplomat, American Board of Internal
Medicine
1984
The American Board of Neurology
July 1986
Bodine Physician Award for top
Medical Resident
1983
Regional speaker for Forest Pharmaceuticals
Advances in Alzheimer’s with Namenda
Regional speaker for Pfizer Pharmaceuticals
Pain management with Lyrica
Migraine treatment with Relpax
Regional speaker for GSK/GlaxoSmithKline
Migraine treatment with Imitrex, Treximet
Regional speaker for Boehringer Ingelheim
Stroke and TIA management with Aggrenox
Neurologic Lecture of North Broward Hospital Dist.
Nursing Association
1988
Comprehensive Management of AIDS patients:
Treatment Team Workshop, Dania FL
1988
Alzheimer’s Association: A Regional
Alzheimer’s Disease Conference;
February 25, 1999
Psycho Pharmacology: Updates on current medications
For dementia and related psychiatric disorders and Behavioral problems.
Neurological Associates
572 East McNab Road, Suite 202
Pompano Beach, FL 33060
1999 – present
TEVA Neuroscience, Protocol TNC GA
Indication - Multiple Sclerosis
2006
Biogen, IDEC & Elan Pharmaceuticals, Protocol 101-MS-322
Indication - Multiple Sclerosis
2006
Takeda Global Research, Protocol 01-05-TL-375-061
Indication - Alzheimer’s disease
2006
Novartis Pharmaceuticals Corp., Protocol Stalevo/CEL200A
Indication - Parkinson’s disease with end-of-dose wearing off
2005 – 2006
Protein Design Labs, Inc., Protocol DAC-1012
Indication- Multiple Sclerosis
2005 – 2006
Myriad Pharmaceuticals, Protocol MPC-7869
Indication- Alzheimer’s disease
2005 – 2006
Acadia Pharmaceuticals, Protocol ACP 103-010
Indication- Parkinson’s disease with psychosis
2005 – 2006
Eisai Medical Research, Protocol TVP-1012-A001-201
Indication- Alzheimer’s disease with Mild to Moderate Dementia
2005 – 2006
Merck Germany, Protocol EMR 62 225 030
Indication- Parkinson’s disease with dyskinesia
2005 – 2006
Merck Germany, Protocol EMR 62 225 019
Indication- Parkinson’s disease with dyskinesia
2004 – 2006
Acadia Pharmaceuticals, Protocol SCP 103-006
Indication- Parkinson’s disease with psychosis
2004 – 2006
Biogen Idec, Protocol C-1808
Indication- Multiple Sclerosis
2004 – 2006
INC Research, Protocol 02-AVR-107
Indication- Pseudobulbar Affect
2002 – 2006
ILEX Pharmaceuticals, Inc., Protocol CAMMS 223
Indication- Multiple Sclerosis
2002 – 2006
Schwarz BioSciences, Protocol SP512
Indication- Parkinson’s Disease
2001 – 2006
Schwarz BioSciences, Protocol SP650
Indication- Parkinson’s Disease
2001 – 2006
Biogen Idec, Protocol C-1802
Indication- Multiple Sclerosis
2001 – 2005
Mylan Pharmaceuticals Inc. Protocol APO401
Indication- Parkinson’s Disease
2000 – 2005
INC Research, Protocol 02-AVR-106
Indication- Pseudobulbar Affect
2002 – 2004
Sention, Inc., Protocol 22018
Indication- Anterior Communicating Artery Aneurysm
2002 – 2003
Serono, Inc., Protocol 22982
Indication- Multiple Sclerosis
2001 – 2002
Janssen Pharmaceuticals Inc., Protocol GAL-USA 23,
Indication- Alzheimer’s Disease
2001 – 2002
Biogen, inc., Protocol C-858
Indication- Multiple Sclerosis
2001
Novartis Pharmaceuticals Inc., Protocol CCOM998 US01
Indication- Parkinson’s Disease
2000 – 2001